Check Your Eligibility
Answer a few questions to see if you may qualify for this trial.
Step 1 of 8
Have you had genetic testing that shows you are HLA-A*02:01 positive, and if so, has your doctor documented why tebentafusp is not the right first-line treatment for you or that you cannot tolerate it?
If you are HLA-A*02:01 positive, tebentafusp is typically the preferred first-line treatment for metastatic uveal melanoma. To join this study, your doctor must document why this standard treatment is not suitable for you or why you cannot tolerate it. This ensures you're being offered the most appropriate therapy.
Show original medical criteria
HLA-A*02:01 positive status with documented rationale for alternative treatment approach
This is informational only — not medical advice. Always discuss eligibility with your oncologist.